Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cytomegalovirus
Findings from Johann Wolfgang Goethe University broaden understanding of cytomegalovirus
July 16th, 2008
"Development of a vaccine against human cytomegalovirus (HCMV) infection has been identified as a high priority goal in biomedical research, yet no vaccine has been licensed until now," investigators in Mainz, Germany report. "Recombinant subviral dense bodies (recDB) are a promising basis for the establishment of such a vaccine. In this article, strategies for the generation of recDB, based on recombination-mediated genetic engineering of the 230 kb HCMV DNA genome in E. coli are outlined," wrote V. Mersseman and colleagues, Johann Wolfgang Goethe University. The researchers concluded: "Analysis of viral mutants that were constructed in this process...
Source: Vaccine Weekly (2008-07-16)
|
